A real-time PCR assay was developed to quantify human cytomegalovirus (CMV) DNA in peripheral blood leukocytes (PBLs) of bone marrow transplantation patients. Unlike other teams, we quantified CMV and the glyceraldehyde-3-phosphate dehydrogenase (GAPDH) gene using a plasmid containing both sequences as an external standard. Tenfold serial dilutions of this plasmid yielded overlapping standard curves that allowed the quantification of CMV and GAPDH gene copies in an efficient and accurate manner. Sequential blood samples (164 specimens) were collected from 16 patients. PBLs were tested by the pp65 antigenemia assay and quantitative CMV and GAPDH gene PCRs. CMV DNA was detected by PCR in 13 patients a mean of 15 days prior to the appearance of antigenemia. The administration of anti-CMV drugs led to a rapid decrease in the numbers of viral copies and positive nuclei. Real-time PCR assay results correlated with those of the CMV pp65 antigenemia assay (P < 0.00001). The TaqMan assay may be a useful tool for rapid quantification of CMV infection and for monitoring of CMV reactivation in bone marrow transplantation recipients.Human cytomegalovirus (CMV) is a well-known cause of mortality in blood and bone marrow transplantation (BMT) patients. Monitoring of CMV reactivation from latency is critical for these patients. Prophylaxis against CMV disease with ganciclovir (8, 9) or foscarnet (16) in asymptomatic BMT recipients has been shown to dramatically reduce the incidence of CMV disease (8, 17). As ganciclovir and foscarnet are myelotoxic and nephrotoxic, respectively, full treatment is often started at the time of documented CMV reactivation. The key to efficient and effective management of CMV infection in these patients is a test capable of rapidly monitoring and quantifying the presence of CMV in the blood. This is particularly essential for the identification of subjects at high risk of developing CMV disease, e.g., patients receiving steroid or immunosuppressive compounds for accelerated graft-versus-host disease and also for the application and monitoring of preemptive antiviral therapeutic strategies. The CMV assays presently available and frequently used in this setting include shell vial culture (7), the CMV antigenemia assay (2), PCR for CMV DNA (3), hybrid capture assay for quantitation of CMV DNA (10), and detection of CMV RNA by nucleic acid sequencebased amplification (1).Among white blood cells, peripheral blood leukocytes (PBLs) are the main CMV carriers during active CMV infection. The detection of CMV antigenemia in PBLs has been shown to be an early marker of CMV infection. A monoclonal antibody is used to detect pp65, the CMV lower matrix phosphoprotein in PBLs, and this test is widely used to monitor BMT recipients. Although a correlation was found between the number of pp65-positive PBLs and the development of clinical symptoms, this method (6, 20) poses a number of problems. It is difficult to perform before engraftment because the number of leukocytes is limited and false-negative results are ...
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.